title: CCK-8S inhibits L-dopa-induced dyskinesias in parkinsonian squirrel monkeys.
abstract: Systemic administration of CCK-8S (1 or 10 micrograms/kg IP) markedly inhibited L-dopa-induced dyskinesias in parkinsonian monkeys, but did not interfere with locomotor stimulation by L-dopa. CCK analogues may be useful antidyskinetic agents for improved control of Parkinson's disease.
authors.affiliation: Merck Sharp & Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK.
authors.forename: S
authors.initials: S
authors.lastname: Boyce
authors.forename: N M
authors.initials: NM
authors.lastname: Rupniak
authors.forename: M
authors.initials: M
authors.lastname: Steventon
authors.forename: S D
authors.initials: SD
authors.lastname: Iversen
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D004195:Disease Models, Animal; D004409:Dyskinesia, Drug-Induced / Q000517:prevention & control*; D007980:Levodopa / Q000627:therapeutic use / Q000633:toxicity*; D010302:Parkinson Disease, Secondary / Q000188:drug therapy*; D012453:Saimiri; D012844:Sincalide / Q000627:therapeutic use*
chemical_list: D007980:Levodopa; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D012844:Sincalide